Treatment of severe pulmonary alveolar proteinosis using inhaled GM-CSF

G. Keir, A. Wells, C. Morgan (London, United Kingdom)

Source: Annual Congress 2010 - Rare diffuse lung diseases

Session: Rare diffuse lung diseases
Session type: Thematic Poster Session
Number: 744

Disease area: Interstitial lung diseases

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
G. Keir, A. Wells, C. Morgan (London, United Kingdom). Treatment of severe pulmonary alveolar proteinosis using inhaled GM-CSF. Eur Respir J 2010; 36: Suppl. 54, 744

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.

Related content which might interest you:

Inhaled GM-CSF for autoimune pulmonary alveolar proteinosis Source: Short video statement 2020 Year: 2020
Treatment of pulmonary alveolar proteinosis (PAP) with administration of GM-CSF Source: Eur Respir J 2002; 20: Suppl. 38, 447s Year: 2002
Pulmonary alveolar proteinosis Source: Respipedia Article Year: 2017
Successful treatment by GMCSF of pulmonary alveolar proteinosis relapsing after a first GMCSF course Source: Eur Respir J 2004; 24: Suppl. 48, 670s Year: 2004
Our cases with pulmonary alveolar proteinosis Source: International Congress 2018 – Pitfalls in the diagnosis and management of rare diffuse parenchymal lung diseases (DPLDs) Year: 2018
Pulmonary alveolar proteinosis: failure of treatment by bronchoscopic lobar lavages and GM-CSF treatment in a child Source: Eur Respir J 2003; 22: Suppl. 45, 309s Year: 2003
Pulmonary alveolar proteinosis Source: Eur Respir Rev 2011; 20: 98-107 Year: 2011
Pulmonary alveolar proteinosis Source: Eur Respir Mon; 2009: 46: 208–224 Year: 2009
Rituximab therapy in autoimmune pulmonary alveolar proteinosis Source: Eur Respir J 2009; 33: 1503-1506 Year: 2009
Pulmonary alveolar proteinosis: from classification to therapy Source: Breathe, 16 (2) 200018; 10.1183/20734735.0018-2020 Year: 2020
Reduced GM-CSF autoantibody in improved lung of autoimmune pulmonary alveolar proteinosis Source: Eur Respir J 2012; 39: 777-780 Year: 2012
Pulmonary alveolar proteinosis and idiopathic pulmonary hemosiderosis Source: International Congress 2019 – CCC Airway diseases Year: 2019
PAS-negative pulmonary alveolar proteinosis Source: Annual Congress 2008 - Rare clinical cases Year: 2008
Lung cysts in pulmonary alveolar proteinosis. Source: International Congress 2018 – Pitfalls in the diagnosis and management of rare diffuse parenchymal lung diseases (DPLDs) Year: 2018
The role of apoptosis in idiopathic pulmonary alveolar proteinosis Source: Annual Congress 2006 - Usefulness of broncoalveolar lavage (BAL) in interstitial lung diseases Year: 2006
The benefits of whole lung lavage in pulmonary alveolar proteinosis Source: Eur Respir J 2004; 23: 503-505 Year: 2004
Mini-whole lung lavage to treat pulmonary alveolar proteinosis (PAP) Source: Virtual Congress 2020 – Addressing unresolved questions in rare diffuse parenchymal lung diseases: interdisciplinary research is the key Year: 2020
Pulmonary alveolar proteinosis and long-term outcome after bronchopulmonary lavage Source: International Congress 2017 – Paediatric bronchology Year: 2017
Inhaled GM-CSF in pulmonary alveolar proteinosis (PAP) patient refractory to plasmapheresis combined with multiple whole lung lavages (WLL) Source: International Congress 2016 – Orphan diseases I Year: 2016